Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC.

ABSTRACT:

Introduction

Durvalumab consolidation therapy is the standard of care after concurrent chemoradiotherapy (CRT) for stage III NSCLC. Immune-related pneumonitis during durvalumab treatment is potentially fatal; however, information is lacking regarding the impact of pneumonitis on patient survival. This study investigates the effect of pulmonary and nonpulmonary immune-related adverse events (irAEs) on the efficacy of durvalumab treatment in patients with stage III NSCLC.

Methods

We retrospectively assessed 158 patients who received durvalumab after CRT at nine Japanese institutions between July 2018 and March 2020. Survival outcomes were compared between patients who developed pneumonitis with those who developed irAEs other than pneumonitis. Patients who survived for less th

SUBMITTER: Kinehara Y 

PROVIDER: S-EPMC10679942 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature